Author

M. G. Dozmorov

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. H. Sawalha· 2 shared B. Hu· 2 shared J. C. Harrell· 2 shared M. A. Alzubi· 2 shared M. Puchalapalli· 2 shared M. Shende· 2 shared S. Bastacky· 2 shared T. H. Turner· 2 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. H. Sawalha

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Inducible deletion of Ezh2 in CD4+ T cells inhibits kidney T cell infiltration and prevents interstitial nephritis in MRL/lpr lupus-prone mice

X. Zheng, M. G. Dozmorov, L. Espinoza, M. M. Bowes, S. Bastacky, A. H. Sawalha

bioRxiv · Mar 4, 2024 · PreprintImmunology

Ezh2 knockout in B cells impairs plasmablast differentiation and ameliorates lupus-like disease in MRL/lpr mice

X. Zheng, M. G. Dozmorov, C. E. Strohlein, S. Bastacky, A. H. Sawalha

This study shows that deleting EZH2 in B cells reduces autoantibody production and improves lupus-like disease in MRL/lpr mice by impairing plasmablast differentiation.

bioRxiv · Jul 21, 2022 · PreprintImmunology

Genomic screening reveals UBA1 as a potent and druggable target in c-MYC-high TNBC models

S. Jacob, T. H. Turner, J. Cai, K. V. Floros, A. K. Yu, C. M. Coon, R. Khatri, M. A. Alzubi, C. T. Jakubik, Y. M. Bouck, M. Puchalapalli, M. Shende, M. G. Dozmorov, S. Boikos, B. Hu, , A. C. Faber

The paper identifies UBA1 as a druggable target in c-MYC-high TNBC models, showing TAK-243 induces ER-stress and apoptosis in vitro and in vivo.

bioRxiv · May 17, 2022Cancer Biology

Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer

J. D. Hampton, E. J. Peterson, S. J. Katner, T. H. Turner, M. A. Alzubi, J. C. Harrell, M. G. Dozmorov, P. J. Gigliotti, V. Kraskauskiene, M. Shende, M. O. Idowu, M. Puchalapalli, B. Hu, L. Litovchick, E. Katsuta, , J. E. Koblinski

This study identifies sulfated glycosaminoglycan (sGAG) levels as a biomarker predicting response to Triplatin in triple-negative breast cancer (TNBC), showing improved efficacy compared to carboplatin in sGAG-high tumors.

bioRxiv · May 5, 2021Pharmacology & Toxicology